Transplant oncology is an emerging field in cancer treatment that applies transplant medicine, surgery, and oncology to improve cancer patient survival and quality of life. A critical concept that must be addressed to ensure the successful application of transplant oncology to patient care is efficient monitoring of tumor burden pre-and post-transplant and transplant rejection. Cell-free DNA (cfDNA) detection has emerged as a vital tool in revolutionizing the management of cancer patients who undergo organ transplantation. The advances in cfDNA technology have provided options to perform a pre-transplant evaluation of minimal residual disease (MRD) and post-transplant evaluation of cancer recurrence and transplant rejection. This review aims to provide a comprehensive overview of the history and emergence of cfDNA technology, its applications to specifically monitor tumor burden at pre-and post-transplant stages, and evaluate transplant rejection.

Original languageEnglish (US)
Article number743
Issue number3
StatePublished - Jan 31 2022


  • Breast cancer
  • Cell-free DNA
  • Cholangiocarcinoma
  • Circulating tumor DNA
  • Colorectal cancers
  • Hepatocellular carcinoma
  • Immunotherapy
  • Liver metastases
  • Liver transplantation
  • Neuroendocrine tumor
  • Transplant oncology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Utility of Cell-Free DNA Detection in Transplant Oncology'. Together they form a unique fingerprint.

Cite this